• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Anderson, Elizabeth
    Ferguson, J E
    Morten, H
    Shalet, Stephen M
    Robinson, E L
    Howell, Anthony
    Affiliation
    Department of Clinical Research, Christie Hospital NHS Trust, Manchester, U.K.
    Issue Date
    1993
    
    Metadata
    Show full item record
    Abstract
    6 patients with advanced breast cancer who had failed first and second line endocrine therapies received bromocriptine (1.25-2.5 mg twice daily per os) and octreotide (Sandostatin) via a continuous subcutaneous infusion (200-400 micrograms/24 h) until disease progression. Pre-treatment 24-h profiles of serum lactogenic hormones and their response to standard provocative tests were established and repeated at 2 weeks, and 3 and 6 months (or at tumour progression). Immunoreactive prolactin (ir-PRL), growth hormone (ir-GH) and insulin-like growth factor I (IGF-I) were measured by radioimmunoassay and bioactive lactogenic hormone levels (BLH) were estimated using the Nb2 rat lymphoma cell bioassay. Before treatment all patients showed episodic secretion of ir-PRL, ir-GH and BLH and provocative stimuli resulted in a peak of ir-GH and BLH maximal between 60 and 90 min after injection but no change in ir-PRL. After 2 weeks of treatment, ir-PRL levels were reduced to below the limit of detection in all 6 patients. Peaks of ir-GH and BLH were still apparent, although much reduced. Immunoreactive PRL continued to be profoundly suppressed in 3 of the 4 patients who remained on treatment for 3 to 6 months. Small pulses of ir-GH were still detectable in these patients with which BLH was, again, well correlated. After 2 weeks of treatment, serum IGF-I levels were reduced by 9-54% of the pretreatment values and generally remained suppressed throughout treatment. Clinically, 4 patients did not show disease progression for periods of up to 6 months and side-effects were minimal.
    Citation
    Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. 1993, 29A (2):209-17 Eur. J. Cancer
    Journal
    European Journal of Cancer
    URI
    http://hdl.handle.net/10541/99801
    DOI
    10.1016/0959-8049(93)90178-I
    PubMed ID
    8422285
    Type
    Article
    Language
    en
    ISSN
    0959-8049
    ae974a485f413a2113503eed53cd6c53
    10.1016/0959-8049(93)90178-I
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives.
    • Authors: Anderson E, Morten H, Wang DY, Burns P, Birch J, Howell A
    • Issue date: 1989 Dec
    • Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer.
    • Authors: Manni A, Boucher AE, Demers LM, Harvey HA, Lipton A, Simmonds MA, Bartholomew M
    • Issue date: 1989 Dec
    • Serum prolactin and growth hormone determined by radioimmunoassay and a two-site immunoradiometric assay: comparison with the Nb2 cell bioassay.
    • Authors: Rose DP, Berke B, Cohen LA
    • Issue date: 1988 Jan
    • Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
    • Authors: Quabbe HJ, Plöckinger U
    • Issue date: 1989 May
    • Bioactive forms of serum lactogens: effects of treatment of prolactinoma patients with bromocriptine.
    • Authors: Rennie PS, Prior JC, Bruchovsky N, Gout PW
    • Issue date: 1985 Jan
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.